Composition for creating vascular occlusions

Abstract

A composition including 2-hexyl cyanoacrylate and gold is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.

1. A composition for creating therapeutic vascular occlusions in an animal comprising a mixture of:
 (a) Part 1 comprised of 2-hexyl cyanoacrylate, hydroquinone, p-methoxyphenol and phosphoric acid; and   (b) Part 2 comprising gold metal powder, ethyl myristate and a sterilized polymer of 2-hexylcyanoacrylate in weak aqueous bicarbonate solution.   
     
     
       2. The composition of  claim 1  wherein Part 1 comprises about 100 PPM hydroquinone, 100 PPM p-methoxyphenol, 250 PPM phosphoric acid and the remainder 2-hexyl cyanoacrylate. 
     
     
       3. The composition of  claim 2  wherein Part 2 comprises about 65 percent by weight gold, about 30 percent by weight ethyl myristate and the remainder said sterilized polymer of 2-hexylcyanoacrylate in weak aqueous bicarbonate solution. 
     
     
       4. The composition of  claim 1  wherein Part 2 includes sulfur dioxide as a stabilizer. 
     
     
       5. A method for creating therapeutic vascular occlusions in an animal needing therapeutic vascular occlusion comprising the steps of:
 (a) Mixing together Part 1 comprised of 2-hexyl cyanoacrylate, hydroquinone, p-methoxyphenol and phosphoric acid with Part 2 comprising gold metal powder, ethyl myristate and a sterilized polymer of 2-hexylcyanoacrylate in weak aqueous bicarbonate solution; and   (b) injecting the mixture into a vascular site needing occlusion with the gold metal powder suspended in the mixture.   
     
     
       6. A composition for creating therapeutic vascular occlusions in an animal comprising a mixture of:
 (a) Part 1 comprising a cyanoacrylate liquid monomer, hydroquinone, p-methoxyphenol and phosphoric acid; and   (b) Part 2 comprising a radiopaque metal powder selected from the group consisting of gold, tantalum and platinum, a large chain fatty acid ester in liquid form and stabilized polymer of cyanoacrylate, wherein the cyanoacrylate is the same as the cyanoacrylate of Part 1.   
     
     
       7. The composition of claim 6, wherein the cyanoacrylate is 2-hexyl cyanoacrylate. 
     
     
       8. The composition of claim 6, wherein the vascular occlusion is created in an arteriovenous malformation (AVM). 
     
     
       9. The composition of claim 6, wherein the fatty acid ester is ethyl myristate. 
     
     
       10. The composition of claim 6, wherein Part 1 comprises 999,550 ppm 2-hexyl cyanoacrylate, 100 ppm hydroquinone, 100 ppm p-methoxyphenol and 250 ppm pure phosphoric acid. 
     
     
       11. The composition of claim 6, wherein Part 1 consists of a cyanoacrylate liquid monomer containing 250 ppm pure phosphoric acid, 100 ppm hydroquinone and 1200 ppm p-methoxyphenol. 
     
     
       12. A method for creating therapeutic vascular occlusions in an animal needing therapeutic vascular occlusion comprising the steps of:
 (a) mixing together Part 1 comprised of cyanoacrylate liquid monomer, hydroquinone, p-methoxyphenol and phosphoric acid with Part 2 comprising a radiopaque metal powder selected from the group consisting of gold, tantalum and platinum, a large chain fatty acid ester in liquid form and a stabilized polymer of cyanoacrylate, wherein the cyanoacrylate is the same as the cyanoacrylate of part 1; and   (b) administering the mixture into a vascular site needing occlusion.   
     
     
       13. The method of claim 12, wherein the cyanoacrylate is 2-hexyl cyanoacrylate. 
     
     
       14. The method of claim 12, wherein the fatty acid ester is ethyl myristate. 
     
     
       15. The method of claim 12, wherein the vascular occlusion is created in an arteriovenous malformation (AVM). 
     
     
       16. The method of claim 12, wherein the administering is by catheter or by percutaneous methods.